Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
The initiation and progression of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH), two severe cardiopulmonary illnesses, are influenced by the interplay of many genes with behaviourial and environmental variables. The long‐term survival rate is still inadequate, despite the fact that the introduction of therapeutic drugs that alter anomalies in the three main pathobiological pathways for PAH has completely changed the way we treat the disease. A growing body of research has shown that a variety of variables, including genetic variants that vary from person to person, influence clinical outcomes and therapeutic responses in PAH. Precision medicine, often referred to as stratified medicine or personalized medicine, offers a lot of potential benefits since it seeks to better focus interventions to the individual while optimizing benefit and reducing damage. Together with the potential and prospects for their usage in the near future, this page attempts to compile and explain the many projects that are now taking place in the PH/PAH sectors.
How to cite this article:
R. Aashish and K.P. Selvarajan Chettiar. Precision Medicine and Personalizing Therapy in Pulmonary Hypertension: Seeing the Light From the Dawn of a New Era.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.12.544.548
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.12.544.548